Sandoz Wants Novo's Prandin Patent Ruled Invalid Again

Law360, New York (August 18, 2011, 7:45 PM EDT) -- Generic-drug maker Sandoz Inc. filed a suit Wednesday in Michigan federal court seeking to have Novo Nordisk Inc.’s patent protecting the diabetes drug Prandin declared — for a second time — invalid and unenforceable.

The suit, seeking declaratory judgment in its favor, comes after a Michigan federal judge in January ruled in a suit filed by generic maker Caraco Pharmaceutical Laboratories Ltd. that Novo's Prandin patent was unenforceable due to inequitable conduct. That ruling was appealed to the Federal Circuit, but the case has been stayed...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.